Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million
The prospectus has today been approved and registered by the Danish Financial Supervisory Authority (Finanstilsynet).NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Scandion Oncology (Scandion or “The Company”), a biotech company developing first-in-class medicines aimed at treating cancer